← Back to Search

Other

M1231 for Esophageal Cancer

Phase 1
Waitlist Available
Research Sponsored by EMD Serono Research & Development Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called M1231 to see if it is safe and effective for patients with advanced cancers, including lung and esophageal cancer. Researchers will study how the drug is processed by the body and its potential to control or reduce the cancer.

Eligible Conditions
  • Metastatic Tumor
  • Esophageal Cancer
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part 2: Cohort B M1231: Metastatic Esophageal Squamous Cell CarcinomaExperimental Treatment1 Intervention
Participants with metastatic esophageal squamous cell carcinoma will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
Group II: Part 2: Cohort A M1231: Metastatic NSCLCExperimental Treatment1 Intervention
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) expressing Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1) on archival tumor tissue will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
Group III: Part 1: M1231Experimental Treatment1 Intervention
Participants with solid tumors for whom no effective standard therapy exists will be included in this Part. Dose escalation of M1231 will be administered as single agent.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
M1231
2021
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

EMD Serono Research & Development Institute, Inc.Lead Sponsor
83 Previous Clinical Trials
22,468 Total Patients Enrolled
Merck KGaA, Darmstadt, GermanyIndustry Sponsor
443 Previous Clinical Trials
114,547 Total Patients Enrolled
Medical ResponsibleStudy DirectorMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
298 Previous Clinical Trials
60,902 Total Patients Enrolled
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top